Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: To compare the effects of intravitreal bevacizumab to those of triamcinolone acetonide injection for the treatment of macular edema secondary to branch retinal vein occlusion. Methods: This retrospective study included 50 eyes of 50 patients who received a single injection of intravitreal bevacizumab (1.25 ㎎/0.05 ㎖, 22 eyes) or triamcinolone acetonide (4 ㎎/0.1 ㎖, 28 eyes) as the only treatment for macular edema secondary to branch retinal vein occlusion; all patients had a post-injection follow-up duration of >24 weeks. Best corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) by optical coherence tomography were measured for up to 24 weeks after injection. Results: BCVA was improved at 1, 4, 8,12 weeks post-injection in the bevacizumab group, and at 1, 4, 8 weeks post-injection in the triamcinolone group. No significant difference was found between the two groups except at 12 weeks. CMT decreased significantly within each group, and no significant difference between groups was found. In the bevacizumab group, no elevated IOP was observed, whereas IOP was significantly increased at 4, 8, and 12 weeks after triamcinolone injection; IOP was therefore significantly different between the two groups. Conclusions: Intravitreal bevacizumab is a comparatively simple treatment method that can effectively improve BCVA and reduce CMT without ocular and systemic complications. Consequently, intravitreal bevacizumab injections may be useful as both an alternative and primary treatment for macular edema secondary to branch retinal vein occlusion.
Abstract
Purpose: To compare the effects of intravitreal bevacizumab to those of triamcinolone acetonide injection for the treatment of macular edema secondary to branch retinal vein occlusion. Methods: This retrospective study included 50 eyes of 50 patients who received a single injection of intravitreal bevacizumab (1.25 ㎎/0.05 ㎖, 22 eyes) or triamcinolone acetonide (4 ㎎/0.1 ㎖, 28 eyes) as the only treatment for macular edema secondary to branch retinal vein occlusion; all patients had a post-injection follow-up duration of >24 weeks. Best corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) by optical coherence tomography were measured for up to 24 weeks after injection. Results: BCVA was improved at 1, 4, 8,12 weeks post-injection in the bevacizumab group, and at 1, 4, 8 weeks post-injection in the triamcinolone group. No significant difference was found between the two groups except at 12 weeks. CMT decreased significantly within each group, and no significant difference between groups was found. In the bevacizumab group, no elevated IOP was observed, whereas IOP was significantly increased at 4, 8, and 12 weeks after triamcinolone injection; IOP was therefore significantly different between the two groups. Conclusions: Intravitreal bevacizumab is a comparatively simple treatment method that can effectively improve BCVA and reduce CMT without ocular and systemic complications. Consequently, intravitreal bevacizumab injections may be useful as both an alternative and primary treatment for macular edema secondary to branch retinal vein occlusion.
참고문헌 (28)
- Weinberg D, "Anatomy of arteriovenous crossing in branch retinal vein occlusion", Am J Ophthalmol, 109, pp.298~302 (1990)
- The Branch Vein Occlusion Study Group, "Argon laser photocoagulation for macular edema in branch vein occlusion", Am J Ophthalmol, 98, pp.271~282 (1984)
- Hayreh SS, "Classification of central retinal vein occlusion", Ophthalmology, 90, pp.458~474 (1983)
- Wallow IH, "Cystoid degeneration in experimental branch vein occlusion", Ophthalmology, 95, pp.1371~1379 (1988)
- Cheng KC, "Intravitreal triamcinolone acetonide for patients with macular edema due to branch retinal vein occlusion", Kaohsiung J Med Sci, 22, pp.321~330 (2006)
- Cakir M, "Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation", Retina, 28, pp.465~472 (2008)
- Nauck M, "Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells", Eur J Pharmacol, 341, pp.309~315 (1998)
- Cekic O, "Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion", Retina, 25, pp.851~855 (2005)
- Battaglia Parodi M, "Grid laser treatment in macular branch retinal vein occlusion", Graefes Arch Clin Exp Ophthalmol, 237, pp.1024~1027 (1999)
- Jaissle GB, "Bevacizumab for treatment of macular edema secondary to retinal vein occlusion", Ophthalmology, 103, pp.471~475 (2006)
- Iturralde D, "Intravitreal bevzcizumab (avastin) treatment of macular edema in central retinal vein occlusion: a short term study", Retina, 26, pp.279~284 (2006)
- Rosenfeld PJ, "Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion", Ophthalmic Surg Lasers Imaging, 36, pp.336~339 (2005)
- Lang GE, "Results of laser coagulations of branch retinal vein occlusions", Klin Monatsbl Augenheilkd, 203, pp.180~188 (1993)
- Estrick E, "Multiple laser treatments for macular edema attributable to branch retinal vein occlusion", Am J Ophthalmol, 139, pp.653~657 (2005)
- Hayreh SS, "Argon laser scatter photocoagulation in treatment of branch retinal vein occlusion: a prospective trial", Ophthalmologica, 206, pp.1~14 (1993)
- Aiello LP, "Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor", Diabetes, 46, pp.1473~1480 (1997)
- Vinores SA, "Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease", Histol Histopathol, 12, pp.99~109 (1997)
- Antonetti DA, "Vascular endothelial growth factor induces rapid phosphrylation of tight junction proteins occluding and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors", J Biol Chem, 274, pp.23463~23467 (1999)
- Rabena MD, "Intravitreal Bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion", Retina, 27, pp.419~425 (2007)
- Wu L, "Comparison of two doses of intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion", Retina, 28, pp.212~219 (2008)
- Badalà F, "The treatment of branch retinal vein occlusion with bevacizumab", Curr Opin Ophthalmol, 19, pp.234~238 (2008)
- Krepler K, "Intravitreal triamcinolone acetonide in patients with macular edema due to central retinal vein occlusion", Acta Ophthalmol Scand, 83, pp.71~75 (2005)
- 최창욱, "망막분지정맥폐쇄로 인한 황반부종에서 허혈성과 비허혈성 간의 유리체강내 스테로이드주사의 효과 차이", 대한안과학회지, 48(1), pp.49~54 (2007), 대한안과학회
- Green WR, "Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases", Retina, 1, pp.27~55 (1981)
- Glacet-Bernard A, "Prognostic factors for retinal vein occlusion: prospectivge study of 175 cases", Ophthalmology, 103, pp.551~560 (1996)
- Clemett RS, "The visual prognosis in retinal branch vein occlusion", Trans Ophthamol Soc UK, 93, pp.523~535 (1973)
- Shilling JS, "Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular edema", Br J Ophthalmol, 68, pp.196~198 (1984)
- 강석재, "망막분지정맥폐쇄에서 황반허혈에 동반된 황반부종의 시력 예후", 대한안과학회지, 43(9), pp.9~1628 (2002), 대한안과학회